U.S. CRISPR And Cas Genes Market Size, Share & Trends Analysis Report By Product & Service, By Application (Biomedical, Agricultural), By End-use (Biotechnology & Pharmaceutical Companies), And Segment ) - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2024-2033

The U.S. CRISPR and Cas genes market size was estimated at USD 1.85 billion in 2023 and is expected to be worth around USD 8.59 billion by 2033, poised to grow at a compound annual growth rate (CAGR) of 16.6% during the forecast period 2024 to 2033.

U.S. CRISPR And Cas Genes Market Size, 2024 to 2033

U.S. CRISPR And Cas Genes Market Key Takeaways

  • In 2023, the product segment held the largest market share of 79.11%.
  • The services segment is expected to experience the most rapid compound annual growth rate.
  • The biomedical application segment held the largest share of 92.25% in 2023.
  • The agriculture segment will exhibit the quickest compound annual growth rate (CAGR) between 2024 and 2033.
  • The biotechnology and pharmaceutical companies segment dominated the market with a share of 50.19% in 2023.
  • The academic and government research institutes are anticipated to grow at a CAGR of 16.1% over the forecast period.

U.S. CRISPR And Cas Genes Market Growth Factors

Therapeutic applications of CRISPR and Cas genes, rising significance for gene editing, and the introduction of anti-CRISPR proteins are boosting market growth. Moreover, CRISPR and Cas genes provide growth prospects for developing novel cancer therapies that boost market expansion.

U.S. CRISPR and Cas genes market accounted for a 63.0% share in the global CRISPR and Cas genes market in 2023. CRISPR technology is preferred for treating various diseases, including cancer and inflammatory and infectious diseases, making it favorable for future biomedical therapeutics. It revolutionizes cancer treatment by enhancing Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy. Unlike traditional methods, the next generation of CAR-T therapies utilizes CRISPR to improve the precision and efficiency of therapeutic and manufacturing processes. This advancement allows for accurate delivery of CAR genes into T-cell DNA, a significant improvement over viral vectors that randomly insert genes. These features of CRISPR-Cas increase its demand in the market.

Furthermore, the increasing investment from government bodies, funding agencies, and biotechnology companies in genomic research is poised to impact the CRISPR market significantly. International funding organizations such as the NIH and Wellcome Trust play a crucial role by providing financial support for genetic studies. This substantial funding is expected to drive the utilization of genetic editing tools in the country, shaping the landscape of the CRISPR market. Furthermore, a report published in June 2022 stated that the U.S. government granted USD 639.0 million to Human Genome Research Institute for R&D in 2022. The institute further requested USD 629.0 million as funding for 2023.

U.S. CRISPR And Cas Genes Market Report Scope

Report Attribute Details
Market Size in 2024 USD 2.16 Billion
Market Size by 2033 USD 8.59 Billion
Growth Rate From 2024 to 2033 CAGR of 16.6%
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered Product & service, application, end-use 
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Key Companies Profiled Genscript ; Mammoth Biosciences, Inc; Editas Medicine, Inc.; Calyxt, Inc.; Caribou Biosciences, Inc; Addgene, Thermofisher Scientific, Inc; Integrated DNA Technologies, Inc; Egenesis; Danaher Corporation; Synthego; Recombinetics, Inc; Origene Technologies, Inc.;Inscripta, Inc.; Intellia Therapeutics, Inc.

 

U.S. CRISPR And Cas Genes Market By Product & Service Insights

In 2023, the product segment held the largest market share of 79.11%. This growth was fueled by the efforts of institutions and key companies to increase research and development activities. This comprises kits& enzymes such as CAS9, CRISPR libraries, antibodies, design tools, and more. Moreover, Vector-based CAS9 products facilitate research experiments, signifying the use of CRISPR/Cas for gene editing. Such applications shift the focus of manufacturers to develop these products, further expanding market growth. Epic Bio unveiled the GEMS (Gene Expression Modulation System) platform in 2022, which offers precise gene expression modification. The GEMS platform contains a vast library of newly discovered modulators combined with advanced functional and computational genomics capabilities. It enables the rapid design of guide RNAs highly targeted to specific genes.

From 2024 to 2033, the services segment is expected to experience the most rapid compound annual growth rate. This growth is fueled by the rising number of licensing agreements with biotech firms, which offer services ranging from cell line engineering and beyond. Moreover, CRISPR-based gene editing companies focus on offering advanced services to fulfill the unmet demand for this market. For instance, in August 2022, Creative Biogene introduced one-stop microbial genome editing services for knock-in, knockout, and foreign gene insertion using a variety of bacteria. These microbial genome editing services maximize customers’ microbial gene sequence efficiency and minimize off-target effects using the advanced CRISPR/Cas 9 platform.

U.S. CRISPR And Cas Genes Market By Application Insights

The biomedical application segment held the largest share of 92.25% in 2023, owing to the increasing popularity of  CRISPR/Cas9 genome editing technology in several areas of biomedical sciences. The market is experiencing profitable growth opportunities thanks to the emergence of different CRISPR-based therapies to treat chronic conditions such as cancer, diabetes, blood disorders, and infectious diseases. Moreover, regulatory approval of these therapies is driving the segment’s growth. For instance, in December 2023, the US FDA approved Casgevy therapy for sickle cell anemia. Casgevy is the first FDA-approved therapy utilizing CRISPR/Cas9, a genome editing technology.

U.S. CRISPR And Cas Genes Market Share, By Application, 2023 (%)

The agriculture segment will exhibit the quickest compound annual growth rate (CAGR) between 2024 and 2033. The rise in awareness of CRISPR-based gene editing in the agriculture sector has led to increasing adoption improvement in crop production. There is an increase in research studies on agriculture products using CRISPR technology. This trend will expand the growth trajectory of this segment.

U.S. CRISPR And Cas Genes Market By End-use Insights

The biotechnology and pharmaceutical companies segment dominated the market with a share of 50.19% in 2023, owing to the increasing development of CRISPR-based products by major biotechnology and pharmaceutical companies for drug and therapy development. The growing adoption of CRISPR technology in these sectors significantly influences the market landscape and drives revenue growth. Additionally, the rise in the number of companies offering gene and gene-editing products and services in recent years is further fueling the revenue growth within this segment.

The academic and government research institutes are anticipated to grow at a CAGR of 16.1% over the forecast period. The increased research and numerous genomics and gene editing studies in academic and government institutes have increased the demand for CRISPR-Cas9. This surge in research activities focusing on gene engineering and its applications is anticipated to drive rapid growth in the forecast period.

U.S. CRISPR And Cas Genes Market Recent Developments

  • In June 2023, researchers from the University of California announced the development of diseases-resistant rice plants using the CRISPR-Cas editing tool. This genetically modified crop would offer anti-fungal resistance and high yield.
  • In January 2023, Ensoma announced the acquisition of Twelve Bio with $85 million in financing.This would help in the development of its in vivo engineered cell therapy platform and accelerate its pipeline of genomic medicines for immuno-oncology and other therapeutic applications.

U.S. CRISPR And Cas Genes Market Top Key Companies:

  • Genscript
  • Mammoth Biosciences, Inc
  • Editas Medicine, Inc.
  • Calyxt, Inc.
  • Caribou Biosciences, Inc
  • Addgene
  • Thermofisher Scientific, Inc
  • Integrated DNA Technologies, Inc
  • Egenesis
  • Danaher Corporation
  • Synthego
  • Recombinetics, Inc
  • Origene Technologies, Inc.
  • Inscripta, Inc.
  • Intellia Therapeutics, Inc.

U.S. CRISPR And Cas Genes Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. CRISPR And Cas Genes market.

By Product & Service 

  • By Product
    • Kits & Enzymes
      • Vector-based Cas
      • DNA-free Cas
    • Libraries
    • Design Tool
    • Antibodies
    • Others
  • By Service
    • Cell Line Engineering
    • gRNA Design
    • Microbial Gene Editing
    • DNA synthesis

By Application 

  • Biomedical
  • Genome Engineering
  • Disease Model Studies
  • Functional Genomics
  • Epigenetics
  • Others
  • Agricultural

By End-use 

  • Biotechnology & Pharmaceutical Companies
  • Academics & Government Research Institutes
  • Contract Research Organizations (CROs)

Frequently Asked Questions

The U.S. CRISPR and Cas genes market size was estimated at USD 1.85 billion in 2023 and is expected to be worth around USD 8.59 billion by 2033

Some of the key factors driving the market include technological advancements in CRISPR & Cas gene system and increased investments in gene editing-based R&D. Moreover, innovative technologies such as karyotyping, neonatal screening, viral screening and others have boosted the demand for gene editing techniques like CRISPR & Cas gene technology.

Some of the key players in the market are Genscript ; Mammoth Biosciences, Inc; Editas Medicine, Inc.; Calyxt, Inc.; Caribou Biosciences, Inc; Addgene Thermofisher Scientific, Inc; Integrated DNA Technologies, Inc; Egenesis; Danaher Corporation; Synthego; Recombinetics, Inc; Origene Technologies, Inc.;Inscripta, Inc.; and Intellia Therapeutics, Inc.

The U.S. CRISPR and cas genes market is expected to grow at a compound annual growth rate of 16.6% from 2024 to 2033

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Segment Definitions
                        1.2.1. Product& Service
                        1.2.2. Application
                        1.2.3. End-use
                        1.2.4. Estimates and forecasts timeline
                    1.3. Research Methodology
                    1.4. Information Procurement
                        1.4.1. Purchased database
                        1.4.2. nova one advisor internal database
                        1.4.3. Secondary sources
                        1.4.4. Primary research
                        1.4.5. Details of primary research
                            1.4.5.1. Data for primary interviews in Italy
                    1.5. Information or Data Analysis
                        1.5.1. Data analysis models
                    1.6. Market Formulation & Validation
                    1.7. Model Details
                        1.7.1. Commodity flow analysis (Model 1)
                        1.7.2. Approach 1: Commodity flow approach
                        1.7.3. Volume price analysis (Model 2)
                        1.7.4. Approach 2: Volume price analysis
                    1.8. List of Secondary Sources
                    1.9. List of Primary Sources
                    1.10. Objectives
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                        2.2.1. Product& Service
                        2.2.2. Application
                        2.2.3. End-use
                    2.3. Competitive Insights
Chapter 3. U.S. CRISPR and Cas Genes Genes Market Variables, Trends, & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent market outlook
                        3.1.2. Related/ancillary market outlook
                    3.2. Market Dynamics
                        3.2.1. Market Driver Analysis
                        3.2.2. Market Restraint Analysis
                    3.3. U.S. CRISPR and Cas Genes Market Analysis Tools
                        3.3.1. Industry Analysis - Porter’s Five Forces
                            3.3.1.1. Supplier power
                            3.3.1.2. Buyer power
                            3.3.1.3. Substitution threat
                            3.3.1.4. Threat of new entrant
                            3.3.1.5. Competitive rivalry
                        3.3.2. PESTEL Analysis
                            3.3.2.1. Political landscape
                            3.3.2.2. Technological landscape
                            3.3.2.3. Economic landscape
Chapter 4. U.S. CRISPR and Cas Genes Market Product & Service Estimates & Trend Analysis
                    4.1. U.S. CRISPR and Cas Genes Market Product& Service Dashboard
                    4.2. U.S. CRISPR and Cas Genes Market Product& Service Movement Analysis
                    4.3. U.S. CRISPR and Cas Genes Market Size & Forecasts and Trend Analyses, 2021 - 2033
                    4.4. Product
                        4.4.1. Kits & Enzymes
                            4.4.1.1. Kits & Enzymes Market, 2021 - 2033
                            4.4.1.2. Vector-based Cas9
                                4.4.1.2.1. Vector-based Cas9 Market, 2021 - 2033
                            4.4.1.3. DNA-free Cas9
                                4.4.1.3.1. DNA-free Cas9 Market, 2021 - 2033
                        4.4.2. Libraries
                            4.4.2.1. Libraries Market, 2021 - 2033
                        4.4.3. Design Tool
                            4.4.3.1. Design Tool Market, 2021 - 2033
                        4.4.4. Antibodies
                            4.4.4.1. Antibodies Market, 2021 - 2033
                        4.4.5. Others
                            4.4.5.1. Other Products Market, 2021 - 2033
                    4.5. Service
                            4.5.1.1. Service Market, 2021 - 2033
                        4.5.2. Cell Line Engineering
                            4.5.2.1. Cell Line Engineering Market, 2021 - 2033
                        4.5.3. gRNA Design
                            4.5.3.1. gRNA Design Market, 2021 - 2033
                        4.5.4. Microbial Gene Editing
                            4.5.4.1. Microbial Gene Editing Market, 2021 - 2033
                        4.5.5. DNA Synthesis
                            4.5.5.1. DNA Synthesis Market, 2021 - 2033
Chapter 5. U.S. CRISPR and Cas Genes Market: Application Estimates & Trend Analysis
                    5.1. U.S. CRISPR and Cas Genes Market Application Dashboard
                    5.2. U.S. CRISPR and Cas Genes Market Application Movement Analysis
                    5.3. U.S. CRISPR and Cas Genes Market Size & Forecasts and Trend Analyses, 2021 - 2033
                    5.4. Biomedical
                        5.4.1. Biomedical Market, 2021 - 2033
                        5.4.2. Genome Engineering
                            5.4.2.1. Genome Engineering Market, 2021 - 2033
                        5.4.3. Disease Model Studies
                            5.4.3.1. Disease Model Studies Market, 2021 - 2033
                        5.4.4. Functional Genomics
                            5.4.4.1. Functional Genomics Market, 2021 - 2033
                        5.4.5. Epigenetics
                            5.4.5.1. Epigenetics Market, 2021 - 2033
                        5.4.6. Others
                            5.4.6.1. Other Biomedical Applications Market, 2021 - 2033
                    5.5. Agricultural
                        5.5.1. Agricultural Market, 2021 - 2033
Chapter 6. U.S. CRISPR and Cas Genes Market: End-use Estimates & Trend Analysis
                    6.1. U.S. CRISPR and Cas Genes Market End-use Dashboard
                    6.2. U.S. CRISPR and Cas Genes Market End-use Movement Analysis
                    6.3. U.S. CRISPR and Cas Genes Market Size & Forecasts and Trend Analyses, 2021 - 2033
                    6.4. Biotechnology & Pharmaceutical Companies
                        6.4.1. Biotechnology & Pharmaceutical Companies Market, 2021 - 2033
                    6.5. Academic & Government Research Institutes
                        6.5.1. Academic & Government Research Institutes Market, 2021 - 2033
                    6.6. Contract Research Organizations (CROs)
                        6.6.1. Contract Research Organizations (CROs) Market, 2021 - 2033
Chapter 7. Competitive Landscape
                    7.1. Recent Developments & Impact Analysis, By Key Market Participants
                    7.2. Company/Competition Categorization
                    7.3. Vendor Landscape
                        7.3.1. List of key distributors and channel partners
                        7.3.2. Key customers
                        7.3.3. Key company market share analysis, 2023
                            7.3.3.1. Company overview
                            7.3.3.2. Financial performance
                            7.3.3.3. Product benchmarking
                            7.3.3.4. Strategic initiatives
                        7.3.4. Genscript
                            7.3.4.1. Company overview
                            7.3.4.2. Financial performance
                            7.3.4.3. Product benchmarking
                            7.3.4.4. Strategic initiatives
                        7.3.5. Mammoth Biosciences, Inc
                            7.3.5.1. Company overview
                            7.3.5.2. Financial performance
                            7.3.5.3. Product benchmarking
                            7.3.5.4. Strategic initiatives
                        7.3.6. Editas Medicine, Inc.
                            7.3.6.1. Company overview
                            7.3.6.2. Financial performance
                            7.3.6.3. Product benchmarking
                            7.3.6.4. Strategic initiatives
                        7.3.7. Calyxt, Inc.
                            7.3.7.1. Company overview
                            7.3.7.2. Financial performance
                            7.3.7.3. Product benchmarking
                            7.3.7.4. Strategic initiatives
                        7.3.8. Caribou Biosciences, Inc.
                            7.3.8.1. Company overview
                            7.3.8.2. Financial performance
                            7.3.8.3. Product benchmarking
                            7.3.8.4. Strategic initiatives
                        7.3.9. Addgene
                            7.3.9.1. Company overview
                            7.3.9.2. Financial performance
                            7.3.9.3. Product benchmarking
                            7.3.9.4. Strategic initiatives
                        7.3.10. Thermofisher Scientific, Inc
                            7.3.10.1. Company overview
                            7.3.10.2. Financial performance
                            7.3.10.3. Product benchmarking
                            7.3.10.4. Strategic initiatives
                        7.3.11. Integrated DNA Technologies, Inc
                            7.3.11.1. Company overview
                            7.3.11.2. Financial performance
                            7.3.11.3. Product benchmarking
                            7.3.11.4. Strategic initiatives
                        7.3.12. Egenesis
                            7.3.12.1. Company overview
                            7.3.12.2. Financial performance
                            7.3.12.3. Product benchmarking
                            7.3.12.4. Strategic initiatives
                        7.3.13. Danaher Corporation
                            7.3.13.1. Company overview
                            7.3.13.2. Financial performance
                            7.3.13.3. Product benchmarking
                            7.3.13.4. Strategic initiatives
                        7.3.14. Synthego
                            7.3.14.1. Company overview
                            7.3.14.2. Financial performance
                            7.3.14.3. Product benchmarking
                            7.3.14.4. Strategic initiatives
                        7.3.15. Recombinetics, Inc
                            7.3.15.1. Company overview
                            7.3.15.2. Financial performance
                            7.3.15.3. Product benchmarking
                            7.3.15.4. Strategic initiatives
                        7.3.16. Origene Technologies, Inc.
                            7.3.16.1. Company overview
                            7.3.16.2. Financial performance
                            7.3.16.3. Product benchmarking
                            7.3.16.4. Strategic initiatives
                        7.3.17. Inscripta, Inc.
                            7.3.17.1. Company overview
                            7.3.17.2. Financial performance
                            7.3.17.3. Product benchmarking
                            7.3.17.4. Strategic initiatives
                        7.3.18. Intellia Therapeutics, Inc.
                            7.3.18.1. Company overview
                            7.3.18.2. Financial performance
                            7.3.18.3. Product benchmarking
                            7.3.18.4. Strategic initiatives

Proceed To Buy

USD 3800
USD 1900
USD 1200

Customization Offered

  • check-img Cross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask To Expert